Pharma giant Pfizer is betting on Biohaven Pharmaceuticals and its migraine drug Nurtec ODT, also known as rimegepant, agreeing to pay $500 million upfront for the rights to commercialize the drug outside the U.S.
“We believe that our collaboration with Pfizer can transform rimegepant into a massive global brand in regions and markets that today we just couldn’t do alone,” said Biohaven CEO Vlad Coric, citing Pfizer’s large global footprint and marketing expertise.